FDA granted Fast Track designation for IO-202, a first-in-class myeloid checkpoint inhibitor targeting leukocyte immunoglobulin-like receptor B4 (LILRB4, also known as ILT3) for the treatment of patients with relapsed or refractory acute myeloid leukemia.
Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib (Jakafi) to standard tyrosine kinase inhibitor treatment for patients with chronic-phase chronic myeloid leukemia significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment. Results were presented at the European School of Haematology’s 26th Annual John...
Research from the Icahn School of Medicine at Mount Sinai provides new insights into acute myeloid leukemia and its resistance to a common treatment. The study, published Oct. 30 in Nature, was led by Eirini Papapetrou, professor of oncological sciences at Icahn Mount Sinai. Acute myeloid leukemia is a devastating blood cancer that starts in...
